Serum Potassium Levels in Hypokalemic Periodic Paralysis
During an attack of hypokalemic periodic paralysis, serum potassium typically drops to 2.1-2.7 mmol/L, with severe cases reaching as low as 0.9-1.8 mmol/L.
Typical Potassium Ranges During Attacks
The research evidence consistently demonstrates specific potassium thresholds during paralytic episodes:
Moderate Hypokalemia (2.5-3.5 mmol/L)
- Most commonly observed in primary hypokalemic periodic paralysis 1
- Case reports document levels of 2.5 mmol/L 2 and 2.7 mmol/L 3, 4 during acute presentations
- These levels are associated with symmetrical or asymmetrical limb weakness
Severe Hypokalemia (<2.5 mmol/L)
- More frequently seen in secondary causes, particularly thyrotoxic periodic paralysis 1
- Documented levels include 2.1 mmol/L 5 and 1.8 mmol/L 6 in confirmed genetic cases
- Quadriparesis correlates with more severe potassium depletion (mean 2.1 mmol/L) compared to paraparesis 1
Life-Threatening Hypokalemia
- The most severe documented case showed potassium of 0.9 mmol/L in thyrotoxic periodic paralysis, which resulted in fatal cardiac arrhythmia 1
- This underscores the critical importance of cardiac monitoring during severe attacks
Clinical Correlation
The degree of weakness correlates with potassium severity:
- Paraparesis: typically moderate hypokalemia (2.5-3.5 mmol/L)
- Quadriparesis: severe hypokalemia (<2.5 mmol/L, mean 2.1 mmol/L) 1
- Recovery time doubles in quadriparesis (
24 hours) versus paraparesis (12 hours) 1
Key Clinical Pitfalls
Do not dismiss potassium levels in the 2.5-3.0 mmol/L range as "not low enough" to cause paralysis—this is the typical range for primary hypokalemic periodic paralysis attacks 2, 3, 1.
Cardiac monitoring is mandatory when potassium drops below 2.5 mmol/L, as arrhythmias become increasingly likely, with documented mortality at extremely low levels 1.
Secondary causes (thyrotoxicosis, renal tubular acidosis, hyperaldosteronism) tend to produce more severe hypokalemia than primary genetic forms 1, 7, requiring more aggressive initial replacement and treatment of the underlying condition.